Martin Fromm - Selected Publications#

h-index 76 (according to Google Scholar, November 2023)
24.317 citations (according to Google Scholar, November 2023)
2022, 2023, 2024: Top 3% Highly Cited Researcher, AD Scientific Index
2023: Top 2% Highly Cited Researcher, Stanford List (Ioannidis et al.)
2015, 2016: Highly Cited Researcher in Pharmacology & Toxicology, Clarivate Analytics

Gessner A, Müller F, Wenisch P, Heinrich MR, König J, Stopfer P, Fromm MF. A metabolomic analysis of sensitivity and specificity of 23 previously proposed biomarkers for renal transporter-mediated drug-drug interactions.
Clin Pharmacol Ther, 2023, 114, 1058-1072 (Impact factor 2022 = 6.700)

Kehl N, Gessner A, Maas R, Fromm MF, Taudte RV. A supervised machine-learning approach for the efficient development of a multi method (LC-MS) for a large number of drugs and subsets thereof: focus on oral antitumor agents.
Clin Chem Lab Med, 2023, epub (Impact factor 2022 = 6,800)

Then MI, Tümena T, Sledziewska A, Gaßmann K-G, Maas R, Fromm MF. Development in prescriptions of contraindicated and potentially harmful QT interval prolonging drugs in a large geriatric inpatient cohort from 2011 to 2021.
Clin Pharmacol Ther, 2023, 113, 435-445 (Impact factor 2022 = 6.700)

Schlichtig K, Dürr P, Dörje F#, Fromm MF#. Medication errors during treatment with new oral anticancer agents: consequences for clinical practice based on AMBORA study.
Clin Pharmacol Ther, 2021, 110: 1075-1086 (Impact factor 2022 = 6.700) (# shared senior authorship)

Dürr P*, Schlichtig K*, Kelz C, Deutsch B, Maas R, Eckart MJ, Wilke J, Wagner H, Wolff K, Preuß C, Brückl V, Meidenbauer N, Staerk C, Mayr A, Fietkau R, Goebell PJ, Kunath F, Beckmann MW, Mackensen A, Neurath MF, Pavel M, Dörje F#, Fromm MF#. The randomized AMBORA trial: impact of pharmacological/ pharmaceutical care on medication safety and patient-reported outcomes during treatment with new oral anticancer agents.
J Clin Oncol, 2021, 39: 1983-1994 (Impact factor 2022 = 45.400) (* and # shared authorships)

Schumann T, König J, Henke C, Willmes DM, Jordan J, Fromm MF, Birkenfeld AL. SLC transporters as potential targets for the treatment of metabolic disease.
Pharmacol Rev, 2020, 72: 343-379 (Impact factor 2022 = 21.100)

Gessner A, di Giuseppe R, Koch M, Fromm MF, Lieb W, Maas R. Trimethylamine-N-oxide (TMAO) determined by LC-MS/MS: distribution and correlates in the population-based PopGen cohort.
Clin Chem Lab Med, 2020, 58: 733-740 (Impact factor 2022 = 6,800)

Müller F, Sharma A, König J, Fromm MF. Biomarkers for in vivo assessment of transporter function.
Pharmacol Rev, 2018, 70: 246-277 (Impact factor 2022 = 21,100)

Müller F, Weitz D, Mertsch K, König J, Fromm MF. Importance of OCT2 and MATE1 for the cimetidine-metformin interaction: Insights from investigations of polarized transport in single- and double-transfected MDCK cells with a focus on perpetrator disposition. Mol Pharmaceut, 2018, 15: 3425-3433 (Impact factor 2022 = 4,900)

Kim RB, Fromm MF, Wandel C, Leake B, Wood AJJ, Roden DM, Wilkinson GR. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.
J Clin Invest 1998, 101: 289-294 (Impact factor 2022 = 15.900; 1.045 times cited)